Investigation of the hematogenous metastasis mechanism in human lung cancer and development of new adjuvant therapy.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09300
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55040:Respiratory surgery-related
• Research Institution: 独立行政法人国立病院機構高崎総合医療センター(臨床研究部) (2020-2021); Gunma University (2019)
• Principal Investigator: Ibe Takashi 独立行政法人国立病院機構高崎総合医療センター(臨床研究部), 臨床研究部, 呼吸器外科 医長 (80826264)
• Co-Investigator(Kenkyū-buntansha): 清水 公裕 信州大学, 学術研究院医学系, 教授 (90375535) ; 河谷 菜津子 群馬大学, 医学部附属病院, 助教 (80805557) ; 六代 範 群馬大学, 大学院医学系研究科, 講師 (20392334) ; 矢島 俊樹 群馬大学, 大学院医学系研究科, 准教授 (20346852)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 肺癌 / 転移 / Vimentin / 次世代シーケンス解析

Outline of Final Research Achievements

The purpose of this study is to elucidate the mechanism of hematogenous metastasis mediated by the Vimentin gene (VIM) by comparative analysis with the parent strain using the lung adenocarcinoma high metastasis strain PC14HM established by us. .. So far, we have established cell lines in which VIM was knocked down and forcibly expressed, and we conducted verification experiments using them at the cell level and mouse level. In addition, we are comprehensively analyzing variable genes by the CAGE method using next-generation sequencing, and we will analyze these results in detail. Finally, we identified the genes responsible for the transcriptional activity of VIM, and conducted verification experiments using molecular biological techniques based on the findings obtained by CAGE analysis.

Free Research Field

腫瘍学

Academic Significance and Societal Importance of the Research Achievements

１）ヒト肺癌高転移細胞株と動物実験モデルを用いて、肺癌におけるVIMの血行性転移機序への関与を解明し、さらにVIMの受容体として作用している可能性があるinsulin growth factor 1 receptor (IGF1R)と、VIMとの関連を明らかにする。
２）抗IGF1R治療により肺腺癌の血行性転移を制御できるかを検証し、肺癌術後に対する新規アジュバント療法の基礎を確立する。